Zhangjie Wang
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2022First federal award
$5.4MFederal grants as PI5 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
5 awards · $5.4M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 16, 2025 | NIH | SBIR Phase II Development of heparan sulfate-based therapeutics to treat inflammatory diseases | $50K | GLYCAN THERAPEUTICS CORPORATION |
| Jul 15, 2024 | NIH | SBIR Phase II Development of heparan sulfate-based therapeutics to treat inflammatory diseases | $1.5M | GLYCAN THERAPEUTICS CORPORATION |
| Sep 6, 2023 | NIH | SBIR Phase II Development of heparan sulfate-based therapeutics to treat inflammatory diseases | $874K | GLYCAN THERAPEUTICS CORPORATION |
| Aug 18, 2023 | NIH | SBIR Phase II Development of analytical methods for glycosaminoglycans from biological sources | $989K | GLYCAN THERAPEUTICS CORPORATION |
| Sep 17, 2022 | NIH | SBIR Phase II Development of analytical methods for glycosaminoglycans from biological sources | $2.0M | GLYCAN THERAPEUTICS CORPORATION |
Peer ranks
Federal funding#244
Awards as PI#417
Patents#273
Companies
- GLYCAN THERAPEUTICS CORPORATIONLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.